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Introduction
The liver is essential for both carbohydrate and lipid
homeostasis. Individuals with type 2 diabetes often
exhibit impairment of insulin action in the liver (1), and
liver-specific inhibition of insulin signaling in mice
results in glucose intolerance and dyslipidemia (2), indi-
cating the physiological importance of hepatic insulin
action in energy homeostasis. Among the signaling mol-
ecules activated by insulin, PI3K plays a key role in the
metabolic actions of this hormone (3, 4). Prevention of
the insulin-induced activation of PI3K in the liver of mice
thus results in glucose intolerance and dyslipidemia (5).
However, the signaling molecules that function down-
stream of PI3K to mediate the metabolic actions of
insulin in living animals have remained unclear.
Two atypical PKC (aPKC) isozymes, PKCλ and PKCζ
(6), have been identified in mammals. We have previous-
ly shown that PKCλ acts downstream of PI3K in PDGF
or insulin signaling in cultured cells (7, 8). Furthermore,
evidence suggests that 3′-phosphoinositide–dependent
kinase-1 (PDK-1), thought to be a key mediator of PI3K
signaling, contributes to the activation of AGC protein
kinases (which include Akt, p70 S6 kinase, p90rsk, and
aPKC) by phosphorylating these enzymes on residues
located in their activation loops (9, 10). On the basis of
these various observations, we hypothesized that PKCλ
participates in insulin action in vivo. To verify this
hypothesis, using homologous recombination, we gen-
erated mice that harbor a PKCλ gene containing loxP
sites. Disruption of the corresponding aPKC genes in
Caenorhabditis elegans and Drosophila melanogaster resulted
in embryonic death (11, 12). As expected, PKCλ-deficient
mice generated from the floxed PKCλ transgenic animals
also died during embryonic development (K. Akimoto 
et al., unpublished observations).
Given that the liver is one of the most important tar-
get organs of insulin, we next generated mice in which
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the floxed PKCλ gene was specifically deleted in the liver
as a result of Cre recombinase expression in this organ.
Characterization of these animals has now revealed that
PKCλmediates the regulatory effect of insulin on hepat-
ic triglyceride content by contributing to the expression
of the gene for sterol regulatory element–binding pro-
tein-1c (SREBP-1c), and that the lack of PKCλ in the liver
results in increased insulin sensitivity.
Methods
Animals. Mice harboring a floxed PKCλ gene in which
exon 5 was flanked by loxP sequences (PKCλlox/+ mice)
were generated by homologous recombination (K. Aki-
moto et al., unpublished observations). Mice that
express Cre recombinase under the control of the
albumin gene promoter (Alb-Cre mice) (13) were pro-
vided by D. LeRoith (Diabetes Branch, National Insti-
tute of Diabetes and Digestive and Kidney Diseases,
NIH, Bethesda, Maryland, USA). We used only male
mice for the present studies. For the fasting-refeeding
experiments, mice in the fasted group were deprived of
food for 24 hours; mice in the refed group were
deprived of food for 24 hours and then allowed access
to food for 12 hours before analysis. The liver X recep-
tor agonist T0901317 (kindly provided by K. Muraka-
mi, Kyorin Pharmaceutical Co., Tokyo, Japan) was
administered daily by oral gavage at a dose of 10 mg/kg
body mass for 4 days. For oral glucose intake experi-
ments, mice deprived of food for 16 hours were loaded
orally with glucose (2 g/kg body mass). For in vivo ade-
novirus-mediated gene transfer experiments, mice were
injected with the indicated adenovirus vector (1 × 108
PFU) via the tail vein 72 hours before experiments.
Analysis of metabolic parameters. Blood glucose and
plasma insulin concentrations were determined as
described (5). For glucose tolerance and insulin toler-
ance tests, mice deprived of food for 16 hours were
injected intraperitoneally with glucose (2 g/kg body
mass); mice in the randomly fed state were injected
intraperitoneally with human regular insulin (0.75
U/kg). Serum leptin and adiponectin concentrations
were measured with a mouse leptin ELISA kit (Mori-
naga Institute of Biological Science, Yokohama, Japan)
and a mouse/rat adiponectin ELISA kit (Otsuka Phar-
maceutical Co. Ltd., Tokyo, Japan), respectively. Serum
cholesterol, triglyceride, and FFA concentrations were
determined with a cholesterol C-II kit, a triglyceride G
kit, and a NEFA C kit, respectively (Wako Pure Chemi-
cal Industries Ltd., Osaka, Japan). For assay of the cho-
lesterol and triglyceride contents of liver or hind limb
skeletal muscle, lipids were extracted from the tissue as
described (14) and the concentrations of the analytes
in the extract were determined with a cholesterol C-II
kit or a triglyceride G kit.
Northern blot, immunoblot, kinase activity, real-time quan-
titative RT-PCR analyses, and primary culture of hepatocytes.
Total RNA (∼15 µg) was subjected to Northern blot
analysis essentially as described (15); autoradiograms
were visualized and signal intensity was quantitated
with a BAS2000 image analyzer (Fujifilm Co., Tokyo,
Japan). The probes for the genes encoding PPAR-α,
acyl-CoA oxidase-1, and uncoupling protein-2 mRNA’s
(mouse full-length cDNAs) were synthesized by PCR;
the other probes were as described (5, 16, 17). Primary
cultures of rat hepatocytes were prepared and subject-
ed to adenovirus infection as described (15).
For assay of the expression of the genes encoding
SREBP-1 and fatty acid synthase, cells infected or not
with adenoviruses were incubated for 6 hours and 20
hours, respectively, with 100 nM insulin or with 10 µM
T0901317; for assay of the expression of the genes
encoding phosphoenolpyruvate carboxykinase-1
(PKC-1) and glucose-6-phosphatase catalytic subunit
(G6PC), cells were incubated for 6 hours with 500 nM
dexamethasone and 0.1 mM pCPT-cAMP in the
absence or presence of 100 nM insulin. Adenovirus
vectors encoding a dominant-negative mutant of
PKCλ (AxCAλKD), WT PKCλ (AxCAλWT) (8), or a
Myc epitope–tagged active form of PI3K (the 110-kDa
catalytic subunit fused with a myristoylation signal
sequence at its NH2-terminus; AxCAMyr-p110) (15,
18) were described previously, and that encoding β-gal
(AxCALacZ) was kindly provided by I. Saito (Universi-
ty of Tokyo, Tokyo, Japan). The antibodies specific for
mouse SREBP-1c were as described (14).
For assay of the abundance of PKCλ and PKCζ, total tis-
sue homogenates were subjected to immunoprecipitation
with antibodies to PKCλ (αλ190) or to PKCζ (αζ170) (8),
and the resulting precipitates were subjected to
immunoblot analysis with antibodies to PKCλ/ι (Trans-
duction Laboratories, Lexington, Kentucky, USA) or to
PKCζ (Life Technologies Inc., Rockville, Maryland, USA),
respectively. Antibodies that recognize both PKCλ and
PKCζ (C-20, a rabbit polyclonal antibody, and C-20-G, a
goat polyclonal antibody) were obtained from Santa
Cruz Biotechnology (Santa Cruz, California, USA). For
immunodepletion of aPKC, liver homogenates were
subjected to three sequential immunoprecipitations for
120 minutes with αλ190 or with αζ170. The super-
natants of the immunoprecipitations were then sub-
jected to immunoprecipitation with C-20-G and the
precipitates were subjected to immunoblot analysis with
C-20. The kinase activity of aPKC was assayed in the
immunoprecipitates with αλ190 or with αζ170 as
described previously (8). For real-time quantitative
reverse transcription and PCR analysis, cDNA synthe-
sized from total RNA was evaluated in a sequence detec-
tor (model 7900; Applied Biosystems, Foster City, Cali-
fornia, USA) with specific primers and SYBR Green PCR
Master Mix (Applied Biosystems). The relative abun-
dance of mRNA’s was calculated with 36B4 mRNA as
the invariant control. The primers used were as follows:
mouse Srebp1a, 5′-GGAACAGACACTGGCCGAGA-3′ (sense)
and 5′-GCATAGGGGGCGTCA-3′ (antisense); mouse
Srebp1c, 5′-ATCGGCGCGGAAGCTGTCGGGGTAGCGTC-3′
(sense) and 5′-ACTGTCTTGGTTGTTGATGAGCTGGAG-
CAT-3′ (antisense). The primers for mouse 36B4 were as
described previously (5).
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Results
Generation of mice with liver-specific deficiency of PKCλ. We
bred PKCλlox/+ mice with Alb-Cre mice (13). We then
bred the PKCλlox/+, Alb-Cre offspring of this cross with
PKCλlox/+ mice. The offspring of this breeding were
born in a Mendelian ratio (PKCλ+/+, n = 12, or 9.9%;
PKCλ+/+, Alb-Cre, n = 14, or 11.6%; PKCλlox/+, n = 29, or
24.0%; PKCλlox/+, Alb-Cre, n = 33, or 27.3%; PKCλlox/lox, 
n = 15, or 12.4%; PKCλlox/lox, Alb-Cre, n = 18, or 14.9%).
Two closely related isoforms comprise aPKC: PKCλ
and PKCζ (6). We first investigated the amounts of
PKCλ and PKCζ in liver homogenates of PKCλ+/+ (WT)
mice. After three sequential immunoprecipitations
with antibodies to PKCλ or to PKCζ, the correspon-
ding isoforms of aPKC were almost completely deplet-
ed from the homogenates (Figure 1a). aPKC protein,
detected by antibodies that recognize both PKCλ and
PKCζ, was present both in the PKCλ -depleted and the
PKCζ-depleted homogenates, suggesting that liver con-
tains both PKCλ and PKCζ. The relative abundance of
each isoform was comparable. The amount of PKCλ in
the liver of PKCλlox/lox, Alb-Cre (L-λKO) mice was
markedly reduced compared with that in the liver of
WT, PKCλ+/+, Alb-Cre (WT-Cre), and PKCλlox/lox (λlox/lox)
animals (Figure 1b). In contrast, the hepatic abundance
of PKCζ was similar among all four genotypes of mice.
Given the similarity in the hepatic expression level of
PKCλ in WT, WT-Cre, and λlox/lox mice, which indicates
that neither the insertion of the loxP sequences in the
PKCλ gene nor the expression of Cre recombinase
alone affected the abundance of PKCλ, we performed
subsequent experiments with L-λKO and λlox/lox mice.
The kinase activity of PKCλ, but not that of PKCζ, was
greatly reduced in the liver of L-λKO mice compared
with that in the liver of λlox/lox mice (Figure 1c). The
abundance of PKCλ in other tissues, including skeletal
muscle, adipose tissue, the pancreas, the lung, and the
kidney, did not differ between L-λKO and λlox/lox mice
(Figure 1d). The abundance of PKCζ in the two geno-
types of mice was similar in all tissues we examined.
The gross appearance and histology of the liver, includ-
ing the arrangement of hepatocytes in plates and the
structure of hepatic lobules, appeared normal in 
L-λKO mice (data not shown). The serum levels of
aspartate aminotransferase, alanine aminotransferase,
alkaline phosphatase, lactate dehydrogenase, and albu-
min also did not differ significantly between L-λKO
and λlox/lox mice (data not shown). These results indicate
that the lack of PKCλ did not affect the development
or general function of the liver.
Metabolic characteristics of L-λKO mice. The body mass,
mass of the liver, and mass of epididymal fat tissue of
L-λKO mice were similar to those of λlox/lox mice (Table
1). The serum concentrations of triglyceride, choles-
terol, FFAs, leptin, and adiponectin in the randomly fed
state also did not differ between mice of the two geno-
types. Although the blood glucose concentration in the
randomly fed state was similar in the two types of mice,
the plasma concentration of insulin in L-λKO mice was
significantly lower than that in λlox/lox mice. Blood glu-
cose concentrations during a glucose tolerance test
were similar in both L-λKO and λlox/lox mice (Figure 2a).
Again, however, the increase in plasma insulin concen-
tration induced by glucose intake was smaller in L-λKO
mice than in λlox/lox animals (Figure 2b). Moreover, the
glucose-lowering effect of exogenously administered
Figure 1
The abundance and kinase activity of PKCλ and PKCζ in mice with liver-specific PKCλ deficiency. (a) Total homogenates prepared from the
liver of 20-week-old PKCλ+/+ mice were subjected to three sequential immunoprecipitations with antibodies to PKCλ (depleted PKCλ) or to
PKCζ (deplete PKCζ). The resultant supernatants were subjected to immunoprecipitation with antibodies to PKCλ, to PKCζ, or with anti-
bodies that recognize both PKCλ and PKCζ (Pan), and the precipitates were subjected to immunoblot analysis with antibodies that recog-
nize both PKCλ and PKCζ (Pan). (b) Total homogenates prepared from the liver of 18-week-old PKCλ+/+ (WT); PKCλ+/+, Alb-Cre (WT-Cre);
PKCλlox/lox (λlox/lox); or PKCλlox/lox, Alb-Cre (L-λKO) mice were subjected to immunoprecipitation with antibodies to PKCλ or to PKCζ, and the
resulting precipitates were subjected to immunoblot analysis with corresponding antibodies. (c) Total homogenates prepared from the liver
of λlox/lox or L-λKO mice were subjected to immunoprecipitation (IP) with antibodies to PKCλ or to PKCζ, and the resulting precipitates were
assayed for kinase activity. (d) Extracts of the indicated tissues prepared from λlox/lox or L-λKO mice were subjected to immunoprecipitation
with antibodies to PKCλ or to PKCζ, and the resulting precipitates were subjected to immunoblot analysis (IB) with corresponding anti-
bodies. Data in a, b, and d are representative of at least three mice of each genotype; those in c are mean ± SEM of values from six mice. 
*P < 0.01 for the indicated comparison (ANOVA).
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insulin was exaggerated in L-λKO mice (Figure 2c).
These observations indicated that the insulin sensitiv-
ity of L-λKO mice was increased.
Altered hepatic gene expression in L-λKO mice. Early events
of hepatic insulin signaling, including phosphorylation
of insulin receptor substrate-1 (IRS-1), IRS-2, and Akt,
did not differ between L-λKO and λlox/lox mice after
bolus injection of insulin (Figure 2d). We have previ-
ously shown that PKCλ contributes to PI3K-dependent
gene expression induced by growth factors (7). We there-
fore examined L-λKO mice for the hepatic expression of
genes that are regulated by insulin. The abundance of
mRNA’s for glucokinase (GCK), PKC-1, and G6PC in
the liver of randomly fed animals was similar in L-λKO
and λlox/lox mice (Figure 2e). However, the amount of
transcripts encoding SREBP-1, a transcription factor
that regulates the expression of genes important in
triglyceride synthesis (19, 20), as well as the amount of
those encoding fatty acid synthase, the gene for which
is regulated by SREBP-1 (19, 20), were reduced by
approximately 50% in the liver of L-λKO mice.
The expression of Srebp1 and its target genes in the liver
is induced when mice are refed after starvation (21, 22), a
treatment that also results in an increase in the circulat-
ing insulin concentration. The increases in the hepatic
expression of Srebp1, Fas, and the gene for stearoyl-CoA
desaturase-1 (SCD-1; another target of SREBP-1) (19)
induced by refeeding were inhibited by about 50%, 35%,
and 25%, respectively, in L-λKO mice (Figure 2f). Of the
two splice variants of Srebp1 mRNA (19), only the abun-
dance of Srebp1c mRNA, not that of Srebp1a mRNA, is
increased in the liver in response to insulin or refeeding
(22). The induction of Srebp1c expression in the liver in
response to refeeding was inhibited by about 50% in 
L-λKO mice (Figure 2g). Moreover, immunoblot analysis
with antibodies specific for SREBP-1c (14) revealed that
the increase in the amount of this protein in a nuclear
fraction of the liver induced by refeeding was markedly
reduced in L-λKO mice (Figure 2h).
We and other investigators have shown that the
effect of insulin on the expression of Srebp1 is mediat-
ed by a PI3K-dependent pathway (15, 23). We therefore
next took advantage of the fact that systemic infusion
of adenoviral vectors results in liver-specific expression
of exogenous genes (5). Infusion of AxCAMyr-p110,
but not of AxCALacZ, resulted in the expression of the
Myr-p110 protein in the liver of both L-λKO and λlox/lox
mice (Figure 2i); expression of Myr-p110 was not
detected in skeletal muscle or adipose tissue (data not
shown). Infusion of AxCAMyr-p110, but not of
AxCALacZ, also resulted in a reduction in the blood
glucose concentration of both L-λKO and λlox/lox mice
in the fasted state, suggesting that activation of hepat-
ic PI3K signaling lowers blood glucose concentration.
However, the glucose-lowering effect of AxCAMyr-
p110 was greater in L-λKO mice than in the control
animals, consistent with our observation that the glu-
cose-lowering effect of exogenously administered
insulin was exaggerated in L-λKO mice.
Although the hepatic expression of Srebp1 and Fas
was induced by the infusion of AxCAMyr-p110 in both
L-λKO and λlox/lox mice (Figure 2j), the extent of this
effect was greatly reduced in the former animals, indi-
cating that PKCλ functions as a downstream effector
of PI3K in the induction of Srebp1c expression in the
liver. Activation of the liver X receptor also increases the
expression of Srebp1c in the liver (16, 24). The hepatic
expression of Srebp1 and Fas induced by gavage with
T0901317, a liver X receptor agonist (24), was similar
in L-λKO and λlox/lox mice (Figure 2k), suggesting that
the lack of PKCλ does not affect the general machinery
responsible for the induction of Srebp1c but rather
results in a specific disruption in PI3K-dependent sig-
naling that leads to increased expression of this gene.
Hepatic lipid content and expression of genes important in 
β-oxidation in L-λKO mice. The triglyceride content of the
liver was reduced (Figure 3a), whereas the hepatic cho-
lesterol content (Figure 3b) and the triglyceride content
of skeletal muscle (Figure 3c) were unchanged in L-λKO
mice in the randomly fed state compared with the cor-
responding values for λlox/lox mice. The synthesis and
breakdown (β-oxidation) of triglyceride are the two
major determinants of hepatic triglyceride content. The
expression of genes that contribute to the oxidation of
triglyceride in the liver, including those encoding 
PPAR-α, acyl-CoA oxidase-1, and uncoupling protein-2,
did not differ between L-λKO and λlox/lox mice in the ran-
domly fed state (Figure 3d), suggesting that the reduced
hepatic triglyceride content of L-λKO mice is attributa-
ble to the reduced expression of Srebp1c.
Hepatic accumulation of glycogen and the induction of
Pck1 and G6pc by starvation/refeeding in L-λKO mice. The
hepatic glycogen content in the randomly fed state
(data not shown) and the increase in hepatic glycogen
content in response to oral glucose intake (Figure 3e)
were similar in L-λKO and λlox/lox mice. The expression
of Pck1 and G6pc in the liver is inhibited by refeeding
after food deprivation. The effect of refeeding on the
Table 1
Phenotypic comparison of λlox/lox and L-λKO mice
Parameter λlox/lox L-λKO
18-week-old mice
Body mass (g) 31.7 ± 0.7 31.8 ± 0.5
Liver mass (g) 1.52 ± 0.03 1.49 ± 0.06
Epididymal fat mass (g) 0.31 ± 0.03 0.34 ± 0.03
12-week-old mice
Blood glucose (mg/dl) 111.3 ± 4.2 119.4 ± 2.2
Plasma insulin (pg/ml) 518 ± 38 356 ± 37A
Serum cholesterol (mg/dl) 107.8 ± 4.4 112.0 ± 4.3
Serum triglyceride (mg/dl) 101.6 ± 8.3 107.4 ± 5.9
Serum FFAs (mEq/l) 0.91 ± 0.07 0.95 ± 0.05
Serum leptin (ng/ml) 1.34 ± 0.26 1.39 ± 0.22
Serum adiponectin (µg/ml) 13.9 ± 0.3 14.6 ± 0.4
Data are from male mice in the randomly fed state at the indicated ages. Val-
ues are mean ± SEM of 15–27 animals. AP < 0.05 vs. λlox/lox (Student’s t test).
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Figure 2
Glucose and insulin tolerance, insulin signaling, and hepatic gene expression in mice with liver-specific deficiency of PKCλ. (a–c) Blood
glucose (a) and plasma insulin (b) concentrations during a glucose-tolerance test in L-λKO and λlox/lox mice at 14 weeks of age, and
blood glucose concentration during an insulin tolerance test at 12 weeks of age (c). Data are mean ± SEM of values from nine to 20
mice. *P < 0.05 vs. the corresponding value for λlox/lox mice (Student’s t test). (d) Tyrosine phosphorylation of IRS-1 and IRS-2 and
serine phosphorylation of Akt in the liver of λlox/lox or L-λKO mice induced by a bolus injection of insulin. Liver homogenates prepared
2 minutes after administration of insulin (5 U/kg of body mass) or saline were subjected to immunoprecipitation with antibodies to
IRS-1 or to IRS-2, and the resulting precipitates were subjected to immunoblot analysis with antibodies to phosphotyrosine (PY).
Alternatively, liver homogenates were subjected directly to immunoblot analysis with antibodies specific for phosphorylated Akt 
(p-Akt). Data are representative of six mice of each genotype. (e–g) Total RNA extracted from the liver of λlox/lox or L-λKO mice (18
weeks of age) in the randomly fed state (n = 8) (e) or after fasting with or without refeeding (n = 4–7) (f and g) was either separately
combined and subjected to Northern blot analysis (e and f) or subjected individually to RT-PCR analysis (g) for the indicated mRNA’s.
Ethidium bromide staining of 28S rRNA is also shown for Northern analysis. *P < 0.01 (ANOVA). (h) The nuclear fraction of liver
homogenates prepared from λlox/lox or L-λKO mice after fasting with or without refeeding was subjected to immunoblot analysis with
antibodies to SREBP-1c. Data shown are from two mice and are representative of four to six animals. (i and j) Mice (λlox/lox or L-λKO)
16–18 weeks of age (n = 10–16) were injected with AxCAMyr-p110 or AxCALacZ and were subsequently deprived of food for 16 hours.
The abundance of Myr-p110 in liver homogenates was then examined by immunoblot analysis with antibodies to Myc (i, upper panel),
blood glucose concentration was determined (i, lower panel), and the amounts of Srebp1 and Fas mRNA’s among separately com-
bined total RNA extracted from the liver were evaluated by Northern analysis (j). *P < 0.05, **P < 0.01 (ANOVA). (k) Total RNA
extracted from the liver of λlox/lox or L-λKO mice treated with either T0901317 or vehicle was separately combined and subjected to
Northern blot analysis for Srebp1 and Fas mRNA’s. Data are shown for two mice and are representative of four animals.
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hepatic expression of these genes was slightly exag-
gerated in L-λKO mice compared with that apparent
in λlox/lox animals (Figure 3f). These results thus sug-
gested that PKCλ signaling is not required for either
the hepatic accumulation of glycogen or for inhibi-
tion of the expression of gluconeogenesis genes in the
liver. The slight enhancement of refeeding-induced
suppression of Pck1 and G6pc expression apparent in
L-λKO mice may be related to the increased insulin
sensitivity of these animals.
Effects of dominant-negative and WT PKCλ on insulin-
induced expression of Srebp1 in cultured hepatocytes. To con-
firm a causal relation between PKCλ deficiency and the
altered hepatic expression of Srebp1 in L-λKO mice, we
examined the effect of PKCλ signaling on the abun-
dance of Srebp1 mRNA in primary cultures of rat hepa-
tocytes. Incubation of the cells with insulin induced an
increase in the amounts of Srebp1 and Fas mRNA’s (Fig-
ure 4a), and this effect was inhibited by adenovirus-
mediated expression of λKD, which acts in a domi-
nant-negative manner (7, 8). Expression of λKD also
inhibited the increase in the amount of Srebp1 mRNA
induced by Myr-p110 (Figure 4b). In contrast, λKD did
not affect either the insulin-induced inhibition of Pck1
and G6pc expression (Figure 4c) or the expression of
Srebp1 induced by T0901317 (Figure 4d), indicating
that PKCλ signaling specifically contributes to insulin-
induced expression of Srebp1. Moreover, expression of
recombinant WT PKCλ increased the abundance of
Srebp1 and Fas mRNA’s in the absence of insulin (Fig-
ure 4e), indicating that PKCλ signaling is sufficient for
the induction of these genes.
Restoration of PKCλ expression reverses the decrease
in hepatic lipid content and the increase in insulin sen-
sitivity in L-λKO mice. To verify that the altered insulin
sensitivity and hepatic triglyceride content of L-λKO
mice are attributable to the lack of PKCλ in the liver, we
restored the hepatic expression of this enzyme in L-λKO
animals. Infusion of AxCAλWT into L-λKO mice result-
ed in the expression of PKCλ in the liver at a level simi-
lar to that apparent in λlox/lox mice (Figure 5a). The
restoration of PKCλ expression in the liver increased
both the abundance of Srebp1 mRNA and the trigly-
ceride content in this organ of L-λKO mice. Blood glu-
cose concentration was similar in L-λKO mice infused
with AxCAλWT or with AxCALacZ and in λlox/lox mice
infused with AxCALacZ or with PBS. The plasma
insulin concentration of L-λKO mice was increased by
infusion of AxCAλWT, but not of AxCALacZ, to an
extent similar to that apparent in λlox/lox mice infused
with AxCALacZ or with PBS (Figure 5b). Moreover, the
enhancement of the glucose-lowering effect of exoge-
nously administered insulin apparent in L-λKO mice
was also reversed by restoration of PKCλ expression in
the liver (Figure 5c). These results thus indicate that the
changes in the expression of Srebp1 and in triglyceride
Figure 3
Hepatic lipid and glycogen content and the expression of genes involved in β-oxidation and gluconeogenesis in mice with liver-specific PKCλ
deficiency. (a–c) Triglyceride (a) and cholesterol (b) content of the liver and triglyceride content of hind limb muscle (c) of L-λKO and λlox/lox
mice in the randomly fed state at 18 weeks of age. Data are expressed as mg analyte/g wet tissue and are the mean ± SEM from seven mice.
*P < 0.05 (Student’s t test). (d) Total RNA extracted from the liver of λlox/lox or L-λKO mice (n = 8) at 18 weeks of age and in the randomly
fed state was separately combined and subjected to Northern blot analysis for mRNA’s encoding PPAR-α, acyl-CoA oxidase-1 (ACOX-1),
and uncoupling protein-2 (UCP-2). (e) Hepatic glycogen content of λlox/lox or L-λKO mice at 20 weeks of age before (Pre) and 2 hours after
(Post) oral glucose intake. Data are mean ± SEM from four to six mice. (f) Total RNA extracted from the liver of λlox/lox or L-λKO mice (18
weeks of age) after fasting with or without refeeding (n = 4–7) was separately combined and subjected to Northern blot analysis with probes
specific for Pck1 or G6pc mRNA’s.
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content in the liver as well as in whole-body insulin sen-
sitivity apparent in L-λKO mice are directly attributable
to the lack of PKCλ in the liver.
Discussion
On the basis of observations with cultured cells (7, 8),
we hypothesized that PKCλ participates in insulin
action in vivo as a downstream effector of PI3K. Our
present results now demonstrate such a function for
PKCλ, at least in the liver. Several of the metabolic
effects of insulin in the liver are exerted through the
regulation of gene expression. We have previously
shown that the regulation by insulin of the expression
of Gck, Srebp1c, G6pc, and Pck1 in mouse liver is medi-
ated by PI3K (5). Of these four genes, each of which
participates in the metabolic actions of insulin, we
have now revealed that the expression of Srebp1c, a key
regulator of fatty acid and triglyceride synthesis (19,
20), is regulated by PKCλ acting downstream of PI3K.
At present, a signaling pathway that links PKCλ and
the expression of Srebp1c remains unclear. Cyclohex-
imide, an inhibitor of general protein synthesis, has
been shown to prevent insulin-induced expression of
Srebp1c in cultured hepatocytes (25), suggesting that
de novo protein synthesis is required for this action of
insulin. PKCλ thus may contribute to induce expres-
sion of such a protein involved in the transcriptional
activation of Srebp1c.
The hepatic expression of Srebp1c induced by refeed-
ing or by an active PI3K was markedly, but not com-
pletely, prevented in L-λKO mice, suggesting that the
induction of Srebp1c is not solely dependent on PKCλ
signaling. Given that the liver expresses both PKCλ and
PKCζ, PKCζ may be responsible for the residual signal-
ing of Srebp1c. A membrane-targeted form of Akt that
exhibits higher kinase activity than does WT Akt
increases the abundance of Srebp1c mRNA when it is
expressed in primary cultured hepatoyctes (23), sug-
gesting that Akt, a downstream effector of PI3K, may
also contribute to the induction of Srebp1c. However, we
have previously shown that the inhibition of endoge-
nous Akt activity with the use of a dominant-negative
mutant of the kinase did not prevent, but rather aug-
mented, insulin-induced expression of Srebp1c (15).
Moreover, in ob/ob mice and a mouse model with
lipodystrophic diabetes, the abundance of Srebp1c
mRNA is increased, whereas insulin-induced phospho-
rylation of Akt is markedly reduced in the liver of these
animals (26). Mice lacking Akt2, a major isoform of Akt
in the liver, have been established (27). The physiologi-
cal importance of Akt in the induction of Srebp1c in vivo
may be revealed by characterization of the mutant mice.
Figure 4
Effects of dominant-negative and WT PKCλ on the expression of Srebp1, Fas, Pck1, and G6pc in primary cultured rat hepatocytes. (a, c, and
d) Cells that had been infected (or not) with an adenoviral vector for a dominant-negative form of PKCλ (AxCAλKD) at the indicated MOI
(in PFU/cell) were incubated in the absence or presence of insulin, dexamethasone (Dex), or T0901317, plus pCPT-cAMP (these two agents
were used to induce the expression of Pck1 and G6pc), as indicated. Total cell lysates were then subjected to immunoblot analysis with anti-
bodies to PKCλ, and total RNA extracted from the cells was subjected to Northern blot analysis with probes specific for Srebp1, Fas, Pck1,
or G6pc mRNA’s. (b) Cells that had been infected (or not) with an adenovirus encoding a constitutively active form of PI3K (AxCAMyr-p110)
at an MOI of three plaque-forming units/cell were then infected with AxCAλKD at the indicated MOI. Total cell lysates were subjected to
immunoblot analysis with antibodies to PKCλ or to Myc (for the detection of Myr-p110), and total RNA extracted from the cells was sub-
jected to Northern blot analysis with a probe specific for Srebp1 mRNA. (e) Cells were infected (or not) with an adenovirus encoding WT
PKCλ (AxCAλWT) at the indicated MOI, after which cell lysates were subjected to immunoblot analysis with antibodies to PKCλ and total
RNA extracted from the cells was subjected to Northern blot analysis with probes specific for Srebp1 or Fas mRNAs. All data are representa-
tive of at least three independent experiments.
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Atypical PKC isozymes are evolutionarily conserved
proteins required for the formation of apical-basal
polarity in cells (28), which is important for the struc-
tural organization and function of organs. However,
the structures of hepatic lobules and hepatocyte plates
and the serum parameters of general liver function
appeared normal in L-λKO mice. This observation may
be attributable to the fact that disruption of the PKCλ
gene was accomplished by Cre recombinase expressed
under the control of the promoter of the albumin gene,
which is a marker gene of fully differentiated hepato-
cytes. A role for PKCλ in the development of cellular
polarity in the liver might be revealed by characteriza-
tion of hepatectomy-induced liver regeneration in 
L-λKO mice, given that the liver regenerates predomi-
nantly through the replication of mature hepatocytes
under this experimental condition (29).
An unexpected finding of the present study was that
L-λKO mice exhibit increased insulin sensitivity. The
tissue-specific disruption of a gene important for
insulin signaling thus paradoxically resulted in an
increase in whole-body insulin sensitivity. A similar
phenomenon has been observed with mice lacking the
insulin receptor specifically in adipose tissue (30).
Restoration of the hepatic expression of PKCλ
reversed this metabolic phenotype of L-λKO mice,
indicating that the lack of PKCλ in the liver is indeed
responsible for the increased insulin sensitivity of
these animals. The precise mechanism that underlies
this phenomenon remains unclear. Evidence suggests
that the alteration of fatty acids/triglyceride metabo-
lism in insulin’s target tissues is an important deter-
minant of insulin sensitivity. The increase in circulat-
ing FFAs leads to insulin resistance and the
accumulation of triglyceride in skeletal muscle (31),
and triglyceride content in the liver or in skeletal mus-
cle negatively correlates with insulin sensitivity in
humans (32, 33). Leptin and adiponectin, the two
major fat-derived hormones, increase insulin sensitiv-
ity and concomitantly reduce hepatic triglyceride con-
tent (probably by promoting fatty acid oxidation) in
an animal model of insulin resistance or in humans
with lipodystrophic diabetes (34–36). Moreover, over-
expression of lipoprotein lipase in liver or skeletal
muscle resulted in an increase in fatty acid metabolites
and consequently in the accumulation of triglyceride
in the respective tissue, as well as insulin resistance
(37). The decrease in the hepatic expression of the
lipogenic genes and the subsequent alterations in fatty
acid metabolism in L-λKO mice may thus be related to
the increased insulin sensitivity of these animals.
TNF-α secreted from adipose tissue is implicated in
the development of obesity-induced insulin resist-
ance (38). Atypical PKC is activated by cytokines,
including TNF-α and IL-1 (39, 40), and directly phos-
phorylates and activates I-κB kinase-β (IKKβ) (41).
Administration of salicylic acid derivatives that
inhibit IKKβ (42) was shown to increase insulin sen-
Figure 5
Effects of adenovirus-mediated restoration of PKCλ expression in the liver of mice with liver-specific PKCλ deficiency on hepatic lipid con-
tent, expression of Srebp1 in the liver, and insulin sensitivity. (a) Twenty-week-old λlox/lox or L-λKO mice (n = 7–9) were injected with PBS or
with adenoviruses encoding either β-gal (LacZ) or WT PKCλ (λWT), as indicated. Total liver homogenates were subsequently subjected to
immunoprecipitation and immunoblot analysis with antibodies to PKCλ (upper panel; data are representative of three experiments). Total
RNA extracted from the liver was separately combined and subjected to Northern blot analysis with a probe specific for Srebp1 mRNA (mid-
dle panel), and hepatic triglyceride content was determined (lower panel; data are shown as mean ± SEM). *P < 0.05 (ANOVA). (b and c)
Twelve-week-old λlox/lox or L-λKO mice were injected with PBS or with adenoviruses encoding either β-gal or WT PKCλ, after which blood glu-
cose and plasma insulin concentrations were determined in the randomly fed state (b) or an insulin tolerance test was performed (c). Data
represent mean ± SEM from six to ten mice. *P < 0.05 for the indicated comparisons (b) or for the comparison of L-λKO mice injected with
the adenovirus encoding β-gal vs. all other conditions.
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sitivity both in rodent models of diabetes and in
human subjects (43, 44). Moreover, heterozygous dis-
ruption of the IKKβ gene ameliorated the insulin
resistance of obese model mice (44). It is therefore
possible that the hepatic deficiency of PKCλ in 
L-λKO mice results in inhibition of a TNF-α/PKCλ/
IKKβ signaling pathway and a consequent increase in
whole-body insulin sensitivity.
Transgenic mice that overexpress lipoprotein lipase
in skeletal muscle or the liver exhibit an impairment of
the insulin-induced increase in PI3K activity associat-
ed with IRS-1 or IRS-2, respectively (37). Moreover,
administration of salicylic acid derivatives enhanced
insulin-induced tyrosine phosphorylation of the
insulin receptor in genetically obese animals (44).
However, we did not detect changes in the insulin-
induced phosphorylation of IRS proteins or of Akt in
the liver of L-λKO mice. Although we cannot exclude
the possibility that a small increase in the extent of
insulin signaling went undetected under our experi-
mental conditions, it is possible that the enhancement
of insulin action apparent in L-λKO mice occurs at a
step other than IRS or Akt phosphorylation. Evidence
suggests that PKCζ participates in a negative feedback
pathway of insulin signaling leading to the phospho-
rylation of IRS proteins in cultured cells (45). Given
that the insulin-induced phosphorylation of IRS pro-
teins was not significantly increased in the liver of 
L-λKO mice, PKCλ appears not to participate in such
a negative feedback pathway in mouse liver.
In summary, we have shown that, among the vari-
ous metabolic actions of insulin, PKCλ specifically
contributes to induction of the expression of Srebp1c
and of its target genes important in triglyceride syn-
thesis in the liver. Animal models of insulin resist-
ance or obesity often manifest increases both in lipid
content and in the expression of Srebp1c in the liver
(26, 46). Reagents that block PKCλ signaling specifi-
cally in the liver might thus prove effective for reduc-
ing hepatic Srebp1c expression and consequently
hepatic triglyceride content, as well as for ameliorat-
ing insulin resistance.
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